Progenics Pharmaceuticals, Inc. (PGNX) And Centre For Probe Development And Commercialization Announce Agreement To Manufacture Targeted Radiotherapeutic Candidate For Ultra-Orphan Indications
4/2/2014 9:16:14 AM
TARRYTOWN, N.Y. and HAMILTON, Ontario, April 1, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), and Centre for Probe Development and Commercialization (CPDC) today announced that Azedra™, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
comments powered by